Marlise R. Luskin, MD, MSCE, discussed treatment options for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and ...

Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.

An expert discusses how recent data on adjuvant anti–PD-1 trials highlight the significance of disease-free survival (DFS) ...

A panelist discusses how the integration of immunotherapy into recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment requires careful patient monitoring for immune-related adverse events ...

A panelist discusses how treatment strategies for recurrent nasopharyngeal carcinoma (NPC) have evolved, with the updated NCCN guidelines now recommending toripalimab plus gemcitabine/cisplatin as ...

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

A panelist discusses how a 48-year-old man with recurrent nasopharyngeal carcinoma (NPC) presents with nasal congestion, ...

An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after ...

Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with ...

Panelists discuss how RATIONALE-305 represents a significant advancement in first-line treatment for advanced gastric cancer ...

Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic castration-resistant prostate cancer.

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...